1. Volume 372, Issue 9647, Pages 1385-1393 (October 2008)
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial 
Prof Anne Katrin Sjølie, DrSci, Prof Ronald Klein, MD, Prof Massimo Porta, PhD, Prof Trevor Orchard, MB, Prof John Fuller, FRCP, Prof Hans Henrik Parving, DrSci, Prof Rudy Bilous, FRCP, Prof Nish Chaturvedi, MD 
The Lancet 
Volume 372, Issue 9647, Pages (October 2008)
DOI: /S (08)
Copyright © 2008 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

3. Figure 2
Cumulative proportion of patients with progression of retinopathy by treatment allocation
The Lancet  , DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

4. Figure 3
Distribution of changes in ETDRS level during study, by treatment group
The Lancet  , DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

5. Figure 4
Cumulative proportion of patients with regression of retinopathy, by treatment group
The Lancet  , DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

6. Figure 5
Cumulative proportion of patients with regression of retinopathy, grouped by retinopathy level at baseline
(A) Microaneurysms only. (B) Mild non-proliferative diabetic retinopathy. (C) Moderate to moderately severe retinopathy.
The Lancet  , DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions